ianalumab

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…

5 months ago